BioPharmSignal logoBioPharmSignal

Biotech News

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Sensei Biotherapeutics (SNSE)Sensei BiotherapeuticsCompany update

6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings – All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort – Favorable safety profile with six cases of mild,

Related news

NRIXNurix Therapeutics2026-06-11 11:00 EST

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

CGEMCullinan Therapeutics, Inc.2026-06-06 09:15 EST

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

KURAKura Oncology2026-07-27 10:32 EST

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

MGNXMacroGenics2026-07-23 20:01 EST

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

LEGNLegend Biotech Corporation2026-06-15 12:00 EST

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

LYELLyell Immunopharma2026-06-12 16:45 EST

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

View all latest news

Sensei Biotherapeutics

Sensei Biotherapeutics is an immuno-oncology company focused on activating the immune system against cancer. Its platform aims to create differentiated cancer treatments through immune modulation.

Recent company news

SNSESensei Biotherapeutics2026-05-15 11:30 EST

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-05-05 11:30 EST

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

SNSESensei Biotherapeutics2026-04-09 11:30 EST

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

SNSESensei Biotherapeutics2026-03-30 11:30 EST

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-03-17 10:00 EST

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
13.85 USD
Market cap
21.6M USD
Exchange
NYSE
Sector
Biopharma
Location
United States